Oragenics, Inc.: Revision history

20 August 2022

• curprev 11:3211:32, 20 August 2022 95.149.241.133 talk 1,058 bytes +11 No edit summary undo

13 August 2022

• curprev 17:0817:08, 13 August 2022 109.180.50.163 talk 1,047 bytes +15 No edit summary undo

9 August 2022

• curprev 17:4017:40, 9 August 2022 >Paris 1,032 bytes +1,032 Created page with "Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weigh..."